RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.

AstraZeneca Plc

A collection of news and information related to AstraZeneca Plc published by this site and its partners.

Top AstraZeneca Plc Articles

Displaying items 23-33
  • Pfizer abandons AstraZeneca takeover attempt after rejection

    Pharmaceutical giant Pfizer Inc. has abandoned its effort to buy British rival AstraZeneca for $117 billion in what would have been the biggest deal ever in the drug industry. The offer represented "full value" for AstraZeneca, the New York drug maker...
  • European stock index reaches 6-year high; Italian, Spanish bonds rise

    European stock index reaches 6-year high; Italian, Spanish bonds rise
    While U.S. and British markets were closed for holidays Monday, stocks rose in Europe. A benchmark of European equities climbed to a six-year high, while Italian and Spanish bonds advanced as policymakers said they would take steps to support economic...
  • Is this how we'll cure cancer?

    Is this how we'll cure cancer?
    For 85% of kids with a terrible cancer called acute lymphoblastic leukemia, chemotherapy is a cure-but not for Emily Whitehead. Diagnosed at 5, she suffered an infection from her first round of chemo and nearly lost her legs. Then the cancer came back;...
  • MedImmune expands research with universities

    MedImmune expands research with universities
    Biotechnology company MedImmune said Tuesday it has expanded a bioresearch collaboration it started with the University of System of Maryland. The Gaithersburg company, a development arm of AstraZeneca, started the partnership with the University of...
  • Horizon Pharma in deal to buy Ireland's Vidara for $660M

    Horizon Pharma in deal to buy Ireland's Vidara for $660M
    Deerfield-based Horizon Pharma Inc. said Wednesday it will move its headquarters to Ireland as part of a reverse merger with Dublin-based Vidara Therapeutics International Inc. valued at $660 million. The deal, which is expected to close mid-year, is...
  • Chronic illness education offered for patients, others in Newport News

    Chronic illness education offered for patients, others in Newport News
    Preventing and managing chronic diseases has taken center stage with local health systems trying to control costs and improve outcomes for patients. Bon Secours Mary Immaculate Hospital offers free diabetes management classes on the second and fourth...
  • FDA says new cholesterol drugs may not need outcome studies

    FDA says new cholesterol drugs may not need outcome studies
    Members of an experimental class of cholesterol-lowering drugs could get U.S. regulatory approval based on their ability to lower "bad" cholesterol, and may not need to show that they reduce the risk of heart attack and stroke, the Food and Drug...
  • FDA approves new diabetes medication

    FDA approves new diabetes medication
    The Food and Drug Administration on Wednesday approved U.S. marketing of the drug dapagliflozin, the second of a new class of medications that aim to improve glycemic control in patients with Type 2 diabetes. The drug will be marketed under the name...
  • Drug maker Merck laying off 8,500 in strategy overhaul

    Drug maker Merck laying off 8,500 in strategy overhaul
    Merck & Co., the second-largest drug maker by sales, said Tuesday it will lay off 8,500 employees in a strategy overhaul to revamp its research and development efforts. That's on top of a previous announcement that the Whitehouse Station, N.J.-based...
  • Inhaling steroids stunts growth, but not much

    Inhaling steroids stunts growth, but not much
    CHICAGO (Reuters) - Adults who took inhaled steroids as children to control their asthma may be shorter than they otherwise would have been, but only by a little, U.S. researchers said on Monday. Results of a long-term asthma study found that children...
  • Big pharma: Few new antibiotics in the works

    Big pharma: Few new antibiotics in the works
    Thirty years ago, when the world faced the terrifying prospect of an untreatable disease known as AIDS, big drugmakers saw an opportunity and raced to develop new medicines. Today, as the world confronts the crisis of antibiotic resistance, the industry...